
Modified C-Reactive Protein For Novel Treatment Of Lupus Nephritis.Award last edited on: 8/30/10
Sponsored Program
SBIRAwarding Agency
NIH : NIDDKTotal Award Amount
$146,716Award Phase
1Solicitation Topic Code
-----Principal Investigator
Meghan NorvellCompany Information
Azano Pharmaceuticals Inc
5901 Indian School Road Northeast
Albuquerque, NM 87110
Albuquerque, NM 87110
(505) 272-7963 |
jmac@azanopharma.com |
www.azanopharma.com |
Location: Single
Congr. District: 01
County: Bernalillo
Congr. District: 01
County: Bernalillo
Phase I
Contract Number: 1R43DK089804-01Start Date: 7/15/10 Completed: 7/14/11
Phase I year
2010Phase I Amount
$146,716Public Health Relevance:
This work will develop a new therapeutic option for lupus nephritis in SLE patients, based on a specific mechanism that may be superior to current therapies.
Thesaurus Terms:
"achievement; Achievement Attainment; Acute; Adverse Effects; Affect; Animals; Antigen-Antibody Complex; Attenuated; Autoimmune Diseases; Binding; Binding (Molecular Function); Biologic Therapy; Biological Response Modifier Therapy; Biological Therapy; C-Reactive Protein; Cancers; Chronic; Clinical; Cystitis; Deposit; Deposition; Development; Diagnosis; Disease; Disorder; Dose; Drugs; Esrd; Early Treatment; Effector Cell; End Stage Renal Failure; End-Stage Kidney Disease; Flare; Goals; Human; Human, General; Immune Complex; Immunosuppressants; Immunosuppressive Agents; Inflammatory; Injection Of Therapeutic Agent; Injections; Kidney; Lead; Life; Lupus Erythematosus Disseminatus; Lupus Erythematosus, Systemic; Lupus Glomerulonephritis; Lupus Nephritis; Malignant Neoplasms; Malignant Tumor; Mammals, Mice; Man (Taxonomy); Man, Modern; Mediating; Medication; Mice; Modeling; Molecular Interaction; Monitor; Morbidity; Morbidity - Disease Rate; Mortality; Mortality Vital Statistics; Murine; Mus; Nephritis; Organ; Organ System; Patients; Pb Element; Pharmaceutic Preparations; Pharmaceutical Agent; Pharmaceutical Preparations; Pharmaceuticals; Pharmacologic Substance; Pharmacological Substance; Phase; Protein Binding; Protein C; Proteins; Proteins, Specific Or Class, C-Reactive; Proteinuria; Protocol; Protocols Documentation; Receptor Protein; Regimen; Renal Disease, End-Stage; Sbir; Sbirs (R43/44); Sle; Sle - Lupus Erythematosus, Systemic; Safety; Serum Proteins; Small Business Innovation Research; Small Business Innovation Research Grant; Sterility; Symptoms; Systemic Lupus Erythematosus; Systemic Lupus Erythmatosus; Testing; Therapeutic; Timeline; Toxicology; Treatment Efficacy; Treatment Side Effects; Urinary System, Kidney; Work; Autoimmune Disorder; Base; Biotherapeutics; Biotherapy; Body System; Cytotoxic; Disease/Disorder; Disseminated Lupus Erythematosus; Drug Candidate; Drug Efficacy; Drug/Agent; Gene Product; Heavy Metal Pb; Heavy Metal Lead; Human Disease; Immunosuppressive; Improved; In Vivo; Macrophage; Malignancy; Meetings; Mouse Model; Mutant; Neoplasm/Cancer; New Therapeutics; Next Generation Therapeutics; Novel; Novel Therapeutic Intervention; Novel Therapeutics; Pre-Clinical; Preclinical; Prevent; Preventing; Prophylactic; Public Health Relevance; Receptor; Receptor Binding; Renal; Response; Side Effect; Standard Care; Sterile; Systemic Lupus Erythematosis; Therapeutic Efficacy; Therapeutically Effective; Therapy Adverse Effect; Treatment Adverse Effect"
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00